Up and Out - Tips on navigating life science relocation

Add this event to your calendar:
30/11/2017 09:45 30/11/2017 12:00 America/Los_Angeles Up and Out - Tips on navigating life science relocation Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA JLABS Bay Area false DD/MM/YYYY

Up and Out - Tips on navigating life science relocation

Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA

November 30, 2017 from 09:45 AM to 12:00 PM (PST)

$10 - $35

Program Overview:
Your innovation is thriving; your company is growing; it is never too early to plan your move up and out. There is a lot to know about building and moving to a new space, but where do you start? Life science real estate and regulations can be a frustrating world to navigate. But, fear not! This workshop is specifically tailored for companies on the move. Representatives from recent JLABS residents that have moved out, experienced leaders, and industry professionals will teach you how to successfully prepare for your company's big move and help you avoid the pitfalls that can slow you down.

Topics to be covered:

  • What you need to know about the relocation process
    • What didn't you expect?
    • What was different?
    • What were the hardest steps?
  • Relocation Schedules
    • Keep an eye on your time line
  • Budgets
    • What did you prepare for?
    • Unexpected costs?
    • Higher than expected costs?
  • Lease Term Obligations
    • What were the strange lease terms?
  • Market Availability
  • Rents
  • Vacancies

This workshop will include real life examples of successful and unsuccessful moves and will point out key things about relocating a Life Science company.

Rick Friday | Senior Vice President, CBRE read bio»
Chris Jacobs | Executive Vice President, CBRE read bio»
Dino Perazzo | Executive Vice President, Director - LSc Practice, CBRE read bio»
Brandon Service | Associate Director, Newmark Cornish & Careyread bio»
Randy Scott | Executive Managing Director, Newmark Cornish & Carey read bio»

Bolyn Hubby | CSO, Agenovir read bio»
Sanford J. Madigan | CEO, Ankasa Regenerative Therapeutics read bio»
Tahir Mahmood | Co-Founder, Applied Molecular Transport read bio»
David Oberkofler | COO, Encoded read bio»
Michon Pinnix | Chief Business Officer, Chimera Bioengineering read bio»
[Moderator] Jim Viola | Innovation Activation Manager, Johnson & Johnson Innovation, JLABS read bio»


8:45 AM | Registration
9:00 AM | Real - Estate Presentation from Newmark Cornish & Carey
9:20 AM | Real - Estate Presentation from CBRE
9:40 AM | JLABS Company Panel Discussion
10:20 AM | Q & A
10:35 AM | Networking
11:00 AM | Program Close

329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Map It

Speaker Biographies

Rick Friday | Senior Vice President, CBRE
Rick Friday is a founding partner of CBRE's Life Science Practice in the San Francisco Bay Area with over 15 years' experience working with life science occupiers and developers.

Rick's extensive experience in strategic planning along with his in depth local market knowledge and industry insight allows him to provide unparalleled representation to his clients in this highly specialized space. His industry experience includes leasing a wide range of specialty labs including biology and chemistry labs, vivarium, clean room and medical device/manufacturing facilities. Clients include a variety of companies ranging from large pharmaceutical companies to small local start-ups.

Over the past decade, Rick has been involved in over 8 million square feet of lease transactions and has consistently ranked as a top performer in the San Francisco Peninsula office.

Chris Jacobs | Executive Vie President, CBRE
With over 25 years of experience in the life science industry, Chris has established himself as one of the most successful and trusted advisors in the San Francisco Bay Area. As a life science expert, Chris offers a unique perspective of the evolving research market with his intimate local knowledge and deep industry relationships. This strong foundation combined with his experience in laboratory specific improvements and transactions empowers Chris' clients with qualified comprehensive representation – from strategic evaluation to transaction negotiations.

His comprehensive approach for clients ranging from large pharmaceutical companies to start-ups provides the expertise to execute custom facility solutions.

As a founding member of CBRE's SF Bay Area Life Science Practice, he is committed to the industry and his client's success.

Dino Perazzo | Executive Vice President, Director - LSc Practice, CBRE
Dino Perazzo serves as Director of CBRE's Global Life Science Practice. Located in the world's largest life science cluster, San Francisco, Dino provides strategic advisory and portfolio planning to major life science organizations on a local, regional and global basis.

Solely focused on life sciences and specialized assets, Dino is able to thoroughly understand his clients' needs and overall business objectives, effectively empowering clients to mitigate risk while leveraging all real estate opportunities in the evolving life science market. He has facilitated many types of pursuits including large lease negotiations, portfolio optimization, specialized build-to-suits, development efforts, property dispositions and acquisitions.

Dino is a recognized real estate authority and advocate within the life science community. In his role with CBRE's Global Life Science Practice, Dino is responsible for new business generation, leading strategic pursuits, and ensuring qualified and consistent client service/interaction. His visionary thinking complements a proven methodology/approach, serving as an invaluable resource to our growing list of respected clients.

Brandon Service | Associate Director, Newmark Cornish & Carey
Brandon Service is an associate director in Newmark Knight Frank's Palo Alto office, where he specializes in representing tenants (startups and large corporate users) on the development and execution of real estate strategies throughout the Bay Area.

Prior to joining Newmark Knight Frank, Mr. Service worked as a senior construction project manager for high-growth technology companies. In this capacity, he managed all aspects of corporate headquarters relocations, vendor negotiations, timelines and budgets. Mr. Service also managed the construction of tenant improvements for projects ranging from small start-ups to multi-building campus headquarters comprising 300,000 square feet or more.

Randy Scott | Executive Managing Director, Newmark Cornish & Carey
Randy Scott joined Newmark Cornish & Carey as an office and R&D leasing specialist in 1984 and has since achieved unparalleled company success. To date, Mr. Scott has negotiated more than 2,300 transactions representing $11.5 billion. In 1992, 1994, 1996, 1997, 1998, 1999 and 2000 he was honored as the R&D Broker of the Year by the Association of Silicon Valley Brokers (ASVB). He has also been a Top Five Producer at Newmark Cornish & Carey for 32 consecutive years and was the Number One Producer from 1991 through 2004. In 2005, he became a partner in Newmark Cornish & Carey.

Mr. Scott has developed unequaled expertise in working with early stage life science companies, from incubation/R&D through clinical trials in structuring appropriate facility strategies. Having completed 350 life science lease transactions, Mr. Scott is clearly established as the leading life science real estate expert in the San Francisco Bay Area. Competitive and focused, Mr. Scott's outstanding real estate performance has earned him an induction into the ASVB Hall of Fame.

Bolyn Hubby | CSO, Agenovir
Dr. Hubby is the CSO of Agenovir, a San Francisco company developing gene editing-based treatments for diseases associated with latent or persistent viral reservoirs. She has 15 years of industry expertise driving innovative technologies into the clinic to address unmet needs in infectious disease and oncology. Prior to Agenovir, she was the vice president of vaccines and antimicrobials at Synthetic Genomics, where she and her colleagues advanced the company's core synthetic biology technology for influenza vaccines into the clinic and developed novel RNA vaccine and antimicrobial platforms to address the rapid spread of infectious disease and the growing global threat of antibiotic resistance. Prior to Synthetic Genomics, Dr. Hubby served as executive director of vaccines at Liquidia Technologies, Inc., where she and her team built a portfolio of programs focused on new approaches to protein, polysaccharide, and RNA-vectored vaccines targeting bacterial and viral pathogens. Before Liquidia, Dr. Hubby was head of discovery immunology at AlphaVax, Inc., where she helped advance a unique RNA-based viral vector to develop vaccines for infectious diseases, biodefense and cancer. Dr. Hubby is an author on numerous issued and pending patents as well as over 20 peer-reviewed publications. She received her Ph.D. in cellular biology from the University of Georgia.

Sanford J. Madigan, Ph.D. | CEO, Ankasa Regenerative Therapeutics
Sandy is CEO of Ankasa, for which he raised a $19M Series A round to support the Company's efforts to bring a recombinant WNT-based therapeutic into the clinic for various orthopedic applications. He brings over 25 years of industry experience to this role and is experienced in venture financings, licensing founding and value-added technologies, and negotiating strategic partnerships and corporate acquisitions.

Concurrently, Sandy also serves as CEO of Sova Pharmaceuticals, a company focused on bringing its development candidate, SV250, into the clinic for the treatment of neuropathic pain, and as a SVP of the Avalon incubator organization, COI Pharmaceuticals, where he is a member of the executive team and founder of Silarus, CadheRx, Iron Horse and PDI. Prior to these roles, Sandy was a founder and the CEO of Strategic Enzyme Applications, a private company established in partnership with Monsanto; a founder and VP Corporate Development for BioVerdant, a venture-backed clean technology company; and a founding member of various Avalon Ventures portfolio companies from earlier funds, including: Ambit Biosciences (IPO, acquired by Daiichi Sankyo), Xenopharm (acquired by Deltagen) and X-Ceptor Therapeutics (acquired by Exelixis).

Dr. Madigan performed his post-doctoral training at The Salk Institute for Biological Studies. He received his Ph.D. in Genetics and his B.S. in Biochemistry from The State University of New York at Stony Brook where, as a graduate student, he was awarded the Abrahams Memorial Award for outstanding potential for basic research.

Tahir Mahmood | Co-Founder, Applied Molecular Transport
Tahir Mahmood co-founded Applied Molecular Transport, where he also led the company's partnering and corporate development activities. With a career that has straddled science and business, Tahir previously led the US West Coast Life Sciences consulting practice at Booz Allen Hamilton and was Managing Director at Lake Sherwood Partners. As a consultant, he advised executives across the spectrum of life sciences, healthcare provider, private and public equity investment, and global health organizations. Tahir is also co-founder and Board Director of MiNDERA, a molecular diagnostics company with a technology platform he co-invented and developed as an investigator at The Scripps Research Institute. He served as Principal Business Analyst at Amgen, supporting BD, M&A and strategic venture fund transactions related to pharmaceutical technology and drug delivery. Earlier, he was at Chienna (acquired by OctoPlus) and IsoTis S.A. (acquired by Integra Life Sciences). Tahir has authored numerous peer-reviewed publications and is inventor on issued and pending patents. He received BASc and MSc degrees from the University of Toronto. He holds a PhD in Chemical & Biomedical Engineering from a collaborative program between the University of Twente (The Netherlands) and Massachusetts Institute of Technology at the Harvard-MIT Division of Health Sciences and Technology and Boston Children's Hospital.

David Oberkofler | COO, Encoded
David Oberkofler is the Chief Operating Officer of Encoded Genomics, a JLABS graduate developing breakthrough medicines with gene regulation technology. David played an instrumental role in the formation of Encoded and its success in raising significant capital from prominent life science venture firms. In his role as COO, David leads the company's operations, finance and legal functions. Prior to joining Encoded, David was an attorney with Hill Wallack LLP where he represented insurance companies and their insureds in complex litigation involving insurance coverage and employment law disputes. David holds a B.A. in Political Science from Rutgers College, Rutgers University and a J.D. from New England Law | Boston.

Michon Pinnix | Chief Business Officer, Chimera Bioengineering
Michon Pinnix currently serves as the Chief Business Officer for Chimera Bioengineering. The company solves the challenges of Chimeric Antigen Receptor T-cells (CAR-Ts) with RNA-based gene regulatory systems allowing us to re-program the "software" of the immune system. We design CAR-T behavior that promises to minimize toxicity, maximize efficacy and extend persistence. In other words, curing cancer using super charged immune cells..

Prior to Chimera, Ms. Pinnix held various roles within Amgen, Theravance BioPharma, and Blackthorn Therapeutics focused on Strategy, Corporate Development and Pre-Commercial and Commercial Operations. She began her career as a Process Engineer in a leadership development program with DuPont in 2001 and joined PwC (formerly PRTM Management Consultants) upon completing business school to focus on Operational Strategy..

In addition to her own professional growth, Michon is committed to inspiring others to access education. She is an active board member with both the West Valley Boys and Girls Club (WVBGC) and the American Association of University Women (AAUW), serving both programs since 2010.

Ms. Pinnix earned a BS in Chemistry from Spelman College, a BS in Chemical Engineering from Georgia Institute of Technology, a MS in Civil and Environmental Engineering from Stanford University, and a MBA from Harvard Business School.

[Moderator] Jim Viola | Innovation Activation Manager, Johnson & Johnson Innovation, JLABS
Jim is responsible for marketing and events for JLABS @ SSF and JLABS @ QB3 in the Bay Area. His role includes creating and coordinating high-quality, diverse and distinctive programming ranging from one-on-one investor meetings, workshops and large panel discussions to networking and social events. Jim manages JLABS largest global event held each year at the J.P. Morgan Healthcare Conference and is in charge of keeping the content fresh and relevant as the year-round curriculum is designed to assist innovators along the product development continuum. Key to the success of JLABS is establishing relationships with the Bio community.

Prior to Joining Johnson & Johnson, Jim spent two decades in the powersports industry as a successful special-event and marketing professional. He held the post of Marketing Direct, at Ducati North America, Operations Manager at Premier Event and various positions at BMW of North America. After years of working closely with retailers, distributors and manufacturers of high-end European products, Jim has developed a unique insight into special events and understands how to successfully integrate these programs into solid marketing plans.

Jim holds a B.S. Chemistry from Muhlenberg College and earned his M.B.A at Rutgers University. He currently is on the advisory board of CELS, a non-profit organization whose goal is to support Canadian life science companies, and participates in various event committees in the bay area.

JLABS Bay Area

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS. About Johnson & Johnson Innovation Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit www.jnjinnovation.com or follow @JNJInnovation.

Event contact

Related content